<DOC>
	<DOC>NCT02510261</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).</brief_summary>
	<brief_title>The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug Be willing and able to comply with the protocolrequired visit schedule and visit requirements and provide written informed consent Any new or uncontrolled condition that could make the patient unsuitable for participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloid Polyneuropathy</keyword>
	<keyword>TTR</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Amyloidosis</keyword>
</DOC>